Fintech

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Globenewswire·March 30, 2026 at 12:01 PM

First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

NY Fed: Mobile Sports Betting Increases Credit Delinquency
PYMNTS
Labor Department Eases 401(k) Alternative Investment Access
PYMNTS
US rule may open trillions in 401(k) to crypto
CoinDesk
Businesses Adapt AI Budgeting to Usage-Based Pricing
PYMNTS

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

NY Fed: Mobile Sports Betting Increases Credit Delinquency

Labor Department Eases 401(k) Alternative Investment Access

US rule may open trillions in 401(k) to crypto

Businesses Adapt AI Budgeting to Usage-Based Pricing